3,769 Shares in Johnson & Johnson $JNJ Purchased by Ibex Wealth Advisors

Ibex Wealth Advisors acquired a new position in Johnson & Johnson (NYSE:JNJ) in the 1st quarter, HoldingsChannel reports. The fund acquired 3,769 shares of the company’s stock, valued at approximately $921,000.

Other hedge funds have also recently modified their holdings of the company. Kestra Advisory Services LLC raised its holdings in shares of Johnson & Johnson by 6.1% in the first quarter. Kestra Advisory Services LLC now owns 424,980 shares of the company’s stock worth $103,882,000 after buying an additional 24,464 shares during the period. Money Concepts Capital Corp boosted its holdings in Johnson & Johnson by 1.8% during the 1st quarter. Money Concepts Capital Corp now owns 51,138 shares of the company’s stock valued at $12,500,000 after acquiring an additional 886 shares during the period. Fidelity D & D Bancorp Inc. grew its position in Johnson & Johnson by 3.4% in the 1st quarter. Fidelity D & D Bancorp Inc. now owns 2,845 shares of the company’s stock valued at $695,000 after acquiring an additional 94 shares during the last quarter. Resona Asset Management Co. Ltd. increased its stake in Johnson & Johnson by 1.0% in the first quarter. Resona Asset Management Co. Ltd. now owns 843,570 shares of the company’s stock worth $205,899,000 after purchasing an additional 8,597 shares during the period. Finally, CFS Investment Advisory Services LLC lifted its position in shares of Johnson & Johnson by 0.9% during the first quarter. CFS Investment Advisory Services LLC now owns 29,187 shares of the company’s stock worth $6,835,000 after purchasing an additional 250 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.7%

Shares of JNJ stock traded down $1.93 on Friday, hitting $257.17. The stock had a trading volume of 6,533,340 shares, compared to its average volume of 8,252,110. Johnson & Johnson has a one year low of $154.80 and a one year high of $269.43. The business has a 50 day moving average price of $237.07 and a 200 day moving average price of $233.05. The company has a market cap of $619.07 billion, a PE ratio of 29.73, a P/E/G ratio of 2.51 and a beta of 0.24. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the prior year, the business earned $2.77 EPS. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts anticipate that Johnson & Johnson will post 11.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 61.97%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on JNJ shares. TD Cowen initiated coverage on shares of Johnson & Johnson in a report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 price target on the stock. Johnson Rice set a $270.00 price objective on shares of Johnson & Johnson in a report on Friday, June 26th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $283.00 to $284.00 and gave the company an “overweight” rating in a research report on Wednesday. Guggenheim raised their target price on shares of Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Finally, Barclays lifted their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $258.13.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bank of America raised its price target on Johnson & Johnson to $263 from $254, signaling continued support for the stock even as the firm kept a neutral rating. Benzinga report on the price target increase
• Positive Sentiment: Johnson & Johnson backed a new heart failure device trial, keeping investor focus on its medtech pipeline and longer-term growth opportunities in electrophysiology and cardiovascular care. JNJ Backs New Heart Failure Device Trial
• Positive Sentiment: Analysts continued to highlight JNJ as a strong dividend and defensive healthcare name, with several notes pointing to the company’s earnings consistency and attractive income profile. TipRanks dividend aristocrat article
• Neutral Sentiment: Investors are also looking ahead to J&J’s upcoming Q2 earnings report, with previews suggesting the company may again beat expectations, but the market is still waiting for actual results. Zacks Q2 earnings preview
• Negative Sentiment: An Illinois appellate court affirmed a $45 million mesothelioma verdict against Johnson & Johnson and Kenvue tied to talc-related asbestos allegations, renewing legal risk concerns that can weigh on the shares. Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.